EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy

Emily E Holladay iD, Amy S Mudano, Fenglong Xie, Jingyi Zhang, Ted R Mikuls, Ken Saag iD, Huifeng Yun iD, Brian LaMoreaux iD, Megan Francis-Sedlak iD, Jeffrey R Curtis iD

Arthritis Care & Research · 2024

DOI: 10.1002/acr.25361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Emily E Holladay und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Urate Oxidase, Gout, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, Horizon Therapeutics (now Amgen Inc.), National Institute of Arthritis and Musculoskeletal and Skin Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to ascertain pegloticase persistence and adverse events associated with concomitant immunomodulatory drug treatment in patients with gout.

Methods

We conducted a retrospective analysis of patients with gout using the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry from January 2016 through June 2020. The first pegloticase infusion defined the index date. Based on concomitant immunomodulatory drug treatment, we identified three exposure groups: (1) immunomodulatory drug initiators (patients initiating an immunomodulatory prescription ±60 days from the index date), (2) prevalent immunomodulatory drug recipients (patients receiving their first immunomodulatory drug prescription >60 days before the index date with at least one prescription within ±60 days of the index date), and (3) immunomodulatory nonrecipients (patients receiving pegloticase without concomitant immunomodulatory drugs). We calculated the proportion of patients who achieved serum urate levels ≤6 mg/dL and who had laboratory abnormalities (white blood cell count

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urate OxidaseGoutRegistriesHumansRetrospective StudiesMaleFemaleMiddle AgedAgedTreatment OutcomeImmunomodulating AgentsGout SuppressantsDrug Therapy, CombinationUric AcidImmunologic FactorsTime FactorsPolyethylene Glycols

Substanzen

Urate OxidasePegloticaseImmunomodulating AgentsGout SuppressantsUric AcidImmunologic FactorsPolyethylene Glycols

Autor:innen und Institutionen

  • University of Alabama at Birmingham.
  • University of Nebraska Medical Center and the VA Nebraska-Western Iowa Health Care System, Omaha.
  • Amgen Inc, Thousand Oaks, California.

ORCID-Profile: Emily E Holladay, Ken Saag, Huifeng Yun, Brian LaMoreaux, Megan Francis-Sedlak, Jeffrey R Curtis

Förderung

  • NIAMS NIH HHS
  • Horizon Therapeutics (now Amgen Inc.)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Holladay, E. E., Mudano, A. S., Xie, F., Zhang, J., Mikuls, T. R., Saag, K., Yun, H., LaMoreaux, B., Francis-Sedlak, M., & Curtis, J. R. (2024). Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. https://doi.org/10.1002/acr.25361

Vancouver

Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, Saag K, et al. Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. 2024. doi:10.1002/acr.25361

BibTeX
@article{Holladay2024,
  author = {Holladay, Emily E and Mudano, Amy S and Xie, Fenglong and Zhang, Jingyi and Mikuls, Ted R and Saag, Ken and Yun, Huifeng and LaMoreaux, Brian and Francis-Sedlak, Megan and Curtis, Jeffrey R},
  title = {Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy},
  journal = {Arthritis Care & Research},
  year = {2024},
  doi = {10.1002/acr.25361}
}
Kostenlos starten →